Sorrento's CCO decamps for a startup; Amgen selling off CO facility;

@FierceBiotech: Bristol-Myers flags an early success for PhIII Opdivo study. Article | Follow @FierceBiotech

@JohnCFierce: Americans want Medicare to negotiate lower drug prices -- (one day it's going to come). More from Reuters | Follow @JohnCFierce

> George Uy, Sorrento Therapeutics ($SRNE) chief commercial officer, is leaving the company to serve as CEO of an unnamed startup. More

> Amgen ($AMGN) is selling off a 692,000-square-foot facility in Colorado, part of cost-cutting effort announced last year through which the company will shed about 430 jobs in the area. News

> Alynlam ($ALNY) has kicked off an open-label extension study for patisiran, a rare disease therapy now in Phase III development. The company expects to report final data next year and submit the treatment for FDA approval in 2017. Item

Medical Device News

@FierceMedDev: Illumina launches new lab service for HiSeq X sequencing systems. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Study finds Philips' ventilator helps reduce hospital readmissions for COPD. Article | Follow @VarunSaxena2

@EmilyWFierce: In 10 years, liquid biopsy test for cancer will be part of routine annual exams, says Guardant Health CEO. More from the WSJ | Follow @EmilyWFierce

> Hospitals launch trial to test AliveCor's iPhone-enabled ECG for diagnosis of heart attacks. Report

> Early study results indicate EndoStim's implant is effective for treating acid reflux. Story

> Stryker to buy Turkish partner in its second hospital bed acquisition in 2015. More

> NIH-backed scientists develop wireless, remote-controlled brain implant. Article

Pharma News

@FiercePharma: We've got a brand new special report today! Top 10 pharma companies in social media. Feature | Follow @FiercePharma

@EricPFierce: ICYMI: Gallant Pharma owner notified in jail by FDA he is disbarred for life from the pharma industry. More from PharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Baxalta tots up winning hemophilia data as new med beats Advate in late-stage trial. More from FiercePharmaMarketing | Follow @CarlyHFierce

> India expands drug pricing with caps for two antibiotics. Story

> Vast majority of consumers want Medicare to negotiate drug prices. Article

> Sanofi preps for 'profitable' dengue vaccine rollout in 20 countries. Report

Animal Health News

> KC Animal Health Corridor investment forum slated for early September. More

> Aratana charts positive results for canine pain drug, predicts 2016 launch. Report

> PetCure spots booming market for radiosurgery in pets with cancer. Story

> Valeant steps into animal health with $800M acquisition of Egypt's Amoun. Article

> Virbac charts strong sales growth, nabs Big Pharma veteran to oversee quality. Item

Biotech IT News

> FDA turns to Google for help spotting adverse events. Report

> Vermillion raises $18.8M to fund escalation of bioinformatics ambitions. News

> Illumina wraps lab automation and software around HiSeq X to lower barrier to mass sequencing. Article

> Report: Danaher nears $30M buyout of computer-aided imaging business. More

> Arivale sets up with $36M, A-list founders and one eye on the R&D potential of its 'dense data clouds.' Story

Pharma Marketing News

> Does high TV ad rotation give patients the wrong idea about drugs? More

> Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer. Item

> AstraZeneca ponies up for heart-attack patients with new Vida Health app. Report

> VC to pharma: Better get on board with digital health marketing. Story

> Lilly adds new Coco the Type 1 monkey tale to its Disney bookshelf. Article

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.